Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor

被引：24
|
作者：
Han, Shuang [1 ]
Zhang, Fei-Fei [2 ]
Qian, Hai-Yan [1 ]
Chen, Li-Li [1 ]
Pu, Jian-Bin [1 ]
Xie, Xin [2 ]
Chen, Jian-Zhong [1 ]
机构：
[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Key Lab Receptor Res, Shanghai 201203, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 93卷
基金：
中国国家自然科学基金;
关键词：
GPCR; Cannabinoid CB2 receptor; Structure-activity relationship; Coumarin; CANNABINOID RECEPTOR; INVERSE AGONISTS; 2-OXOQUINOLINE DERIVATIVES; ENDOCANNABINOID SYSTEM; ANTIPRURITIC AGENT; IN-VITRO; ANTAGONISTS; DISCOVERY; PAIN; POTENT;
D O I：
10.1016/j.ejmech.2015.01.054
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The CB2 receptor has been considered as an inspiring drug target for the treatment of pain and immune-related diseases. In the current manuscript, a novel series of coumarin derivatives is reported to be designed and synthesized by combining the structural features of some known ligands for the cannabinoid receptors based on the CoMFA model of the lead compounds. The compounds were evaluated to be highly selective ligands for the CB2 receptor over the CBI receptor by calcium mobilization assays. Furthermore, SAR results indicate that the functionality of a ligand is controlled by the substituent on the nucleus. Therefore, molecular docking simulations were performed to calculate the receptor-ligand interactions of our synthesized compounds binding to the CB2 receptor. The understanding of the binding modes could be advantageous for further development of selective ligands for the CB2 receptor. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：16 / 32
页数：17
相关论文
共 50 条
  • [1] Design, synthesis, and structure-activity relationships of diindolylmethane derivatives as cannabinoid CB2 receptor agonists
    Mahardhika, Andhika B. B.
    Ressemann, Anastasiia
    Kremers, Sarah E. E.
    Castanheira, Mariana S. Gregorio S.
    Schoeder, Clara T. T.
    Mueller, Christa E. E.
    Pillaiyar, Thanigaimalai
    ARCHIV DER PHARMAZIE, 2023, 356 (03)
  • [2] Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies
    Qian, Hai-Yan
    Wang, Zhi-Long
    Xie, Xiao-Yu
    Pan, You-Lu
    Li, Gang-Jian
    Xie, Xin
    Chen, Jian-Zhong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 137 : 598 - 611
  • [3] The search for selective ligands for the CB2 receptor
    Huffman, JW
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (13) : 1323 - 1337
  • [4] Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor
    Gado, Francesca
    Mohamed, Kawthar A.
    Meini, Serena
    Ferrisi, Rebecca
    Bertini, Simone
    Digiacomo, Maria
    D'Andrea, Felicia
    Stevenson, Lesley A.
    Laprairie, Robert B.
    Pertwee, Roger G.
    Manera, Clementina
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [5] Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties
    Ghonim, Aya E.
    Ligresti, Alessia
    Rabbito, Alessandro
    Mahmoud, Ali Mokhtar
    Di Marzo, Vincenzo
    Osman, Noha A.
    Abadi, Ashraf H.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 180 : 154 - 170
  • [6] Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor
    Romero-Parra, Javier
    Mella-Raipan, Jaime
    Palmieri, Vittoria
    Allara, Marco
    Torres, Maria Jose
    Pessoa-Mahana, Hernan
    Iturriaga-Vasquez, Patricio
    Escobar, Rossy
    Faundez, Mario
    Di Marzo, Vincenzo
    Pessoa-Mahana, C. David
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 124 : 17 - 35
  • [7] MEDI 164-Novel selective CB2 receptor ligands, Part IX: Pyridine derivatives 2
    Saeui, Christopher T.
    Chu, Guo Hua
    Worm, Karin
    Weaver, Damian G.
    Zhou, Q. Jean
    Goodman, Allan J.
    Green, Rosalyn
    Broadrup, Robert L.
    Dulay, Doreen-Marie S.
    Le Bourdonnec, Bertrand
    Sellitto, Ian F.
    Ajello, Christopher W.
    Leister, Lara K.
    O'Hare, Heather
    Cassel, Joel A.
    Stabley, Gabriel J.
    DeHaven, Robert N.
    Conway-James, Nathalie C.
    LaBuda, Christopher J.
    Koblish, Michael
    Little, Patrick J.
    Brogdon, Bernice L.
    Smith, Steven A.
    Dolle, Roland E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [8] Design, synthesis and structure-activity relationship of novel coumarin derivatives
    Guan, Ai-Ying
    Liu, Chang-Ling
    Li, Miao
    Zhang, Hong
    Li, Zhi-Nian
    Li, Zheng-Ming
    PEST MANAGEMENT SCIENCE, 2011, 67 (06) : 647 - 655
  • [9] The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives
    Omura, Hirofumi
    Kawai, Makoto
    Shima, Akiko
    Iwata, Yasuhiro
    Ito, Fumitaka
    Masuda, Tsutomu
    Ohta, Atsuko
    Makita, Naoya
    Omoto, Kiyoyuki
    Sugimoto, Hiromi
    Kikuchi, Akira
    Iwata, Hiroshi
    Ando, Kazuo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (11) : 3310 - 3314
  • [10] Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists
    Shu, Shuangjie
    Cai, Xiaoqing
    Li, Jia
    Feng, Yang
    Dai, Antao
    Wang, Jiang
    Yang, Dehua
    Wang, Ming-Wei
    Liu, Hong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (12) : 2852 - 2863
12345